Jorge Rodríguez

Mr. Jorge Rodríguez


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
JRJorge Rodríguez
Jorge Rodríguez
RARosa Andreu
Rosa Andreu
RDRoberto Daza
Roberto Daza
LFLucía Fernández-Arroyo
Lucía Fernández-Arroyo
AHAna Hernández-García
Ana Hernández-García
MCMaría J. Calzada
María J. Calzada
In chronic respiratory diseases (CRDs), oxidative stress and inflammation are closely linked, driving disease onset, progression, and comorbidities. Oxidative stress activates inflammatory pathways, while chronic inflammation promotes further reactive oxygen species (ROS) production, creating a vicious cycle leading to airway remodeling, reduced lung function, and exacerbations. This review highlights the central roles of inflammation and oxidative stress in chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). In COPD, chronic hypoxemia associates with emphysema, appearing with disease progression. In OSA, beyond systemic consequences, pulmonary inflammation and oxidative stress contribute to lung injury as well. Although COPD and OSA are distinct conditions, some patients present with “overlap syndrome”, a term used in this review to describe the coexistence of both. This combination poses unique diagnostic and therapeutic challenges. We also examine the role of hypoxia and its transcriptional effects via hypoxia-inducible factors (HIFs) in promoting oxidative stress and inflammation. Finally, we explore how artificial intelligence (AI) offers promising tools to improve diagnosis, monitoring, and management of CRDs and may help elucidate mechanistic links between hypoxia, inflammation, and oxidative stress, contributing to more personalized therapeutic strategies.

10 June 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
JRJorge Rodríguez
Jorge Rodríguez
RARosa Andreu
Rosa Andreu
LSLeila Pérez Sánchez
Leila Pérez Sánchez
AHAna Hernández-García
Ana Hernández-García
CMCecilia Muñoz-Calleja
Cecilia Muñoz-Calleja
MCMaría J. Calzada
María J. Calzada
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMCs), we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, potentially contributing to the dysregulated contractile response of cells. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the endoplasmic reticulum (ER) calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.

15 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JRJorge Rodríguez
Jorge Rodríguez
RARosa Andreu
Rosa Andreu
LSLeila Pérez Sánchez
Leila Pérez Sánchez
AHAna Hernández-García
Ana Hernández-García
CMCecilia Muñoz-Calleja
Cecilia Muñoz-Calleja
MCMaría J. Calzada
María J. Calzada
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMC) we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, this potentially contributing to cell dysregulated contractile response. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the RE calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.

15 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JRJorge Rodríguez
Jorge Rodríguez
RARosa Andreu
Rosa Andreu
RDRoberto Daza
Roberto Daza
LFLucía Fernández-Arroyo
Lucía Fernández-Arroyo
AHAna Hernández-García
Ana Hernández-García
MCMaría J Calzada
María J Calzada
In chronic respiratory diseases (CRDs), oxidative stress and inflammation exhibit a strong pathophysiological interplay, playing essential roles in the onset and progression of these conditions and their associated comorbidities. Oxidative stress can activate inflammatory pathways, leading to sustained airway inflammation. In turn, chronic inflammation can increase the production of reactive oxygen species (ROS), thereby exacerbating oxidative stress. This vicious cycle contributes to airway remodeling, reduced lung function, and disease progression. This review emphasizes the central roles of inflammation and oxidative stress in two of the most prevalent hypoxemic conditions, chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), as well as their involvement in the development of major comorbidities. A comprehensive understanding of these processes is crucial to developing therapeutic strategies aimed at reducing oxidative stress and inflammation for the effective management and treatment of CRDs and their comorbidities. It also underscores the crucial role of hypoxia and its transcriptional effects, mediated by hypoxia-inducible factors (HIF), as a primary driver of disease progression through the promotion of oxidative stress and inflammation. Another key element is the rapid advancement of Artificial Intelligence (AI), which presents promising strategies to mitigate the global burden of CRDs. AI holds potential for reducing healthcare costs while improving diagnostic specificity, enabling earlier detection, and optimizing disease monitoring and management. This review explores the current landscape and future prospects of AI in transforming the diagnosis, clinical management, and prognosis of these respira-tory disorders.